rAAV Vector Intron Optimization for Propionic Acidemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for propionic acidemia (PA) face challenges in achieving high transgene expression levels, leading to the need for high vector doses and increased risk of immune responses, which complicates effective treatment.
Innovation Solution
Incorporating a human β-globin IVS2 intron sequence into recombinant adeno-associated virus (rAAV) vectors for PA treatment, enhancing transgene expression and reducing the required vector dose by optimizing the vector genome composition with specific sequences and elements such as promoters, introns, and capsids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high vector doses are used to achieve sufficient transgene expression, then therapeutic efficacy is improved, but immune responses are increased
Solution Approach 1:
The patent changes the structural parameters of the vector genome by incorporating specific intron sequences (particularly human β-globin IVS2) and optimizing promoter elements. This structural modification enables the system to achieve the same therapeutic efficacy at lower vector doses, thereby reducing immune responses while maintaining treatment effectiveness
Solution Approach 2:
The patent creates a composite vector genome structure combining multiple functional elements: specific intron sequences (human β-globin IVS2), optimized promoters (CBA, CMV), polyadenylation signals, and ITRs. This composite design synergistically enhances transgene expression efficiency, allowing reduced dosing while maintaining therapeutic benefit
2Adaptability or versatility
If alternative intron sequences are used in rAAV vectors, then vector design flexibility is improved, but transgene expression levels are reduced
Solution Approach 1:
The patent systematically evaluates and optimizes intron sequence parameters by testing multiple alternatives (human β-globin IVS1, IVS2, IVS3; bovine growth hormone intron). The discovery that IVS2 specifically enhances expression demonstrates that precise parameter selection within the intron category dramatically impacts transgene productivity
Solution Approach 2:
The patent applies local quality optimization by selecting specific functional elements at specific positions within the vector genome. The human β-globin IVS2 intron is placed in the 5' untranslated region, and specific promoter sequences are positioned upstream of the transgene. This localized optimization of specific genomic regions maximizes overall expression efficiency
Data Source
AI summary
This present disclosure provides recombinant adeno-associated virus (rAAV) and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a rAAV of the invention and a pharmaceutically acceptable carrier or excipient. These pharmaceutical compositions may be useful in gene therapy for the treatment of PA caused by a mutation in propionyl-CoA carboxylase α-subunit (PCCA) or a mutation in propionyl-CoA carboxylase β-subunit (PCCB).